These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31229175)

  • 1. Pharmacological treatments of augmentation in restless legs syndrome patients.
    Trenkwalder C; Paulus W
    Adv Pharmacol; 2019; 84():255-265. PubMed ID: 31229175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management.
    García-Borreguero D
    Sleep Med Clin; 2015 Sep; 10(3):287-92, xiii. PubMed ID: 26329438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
    Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
    Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic augmentation of restless legs syndrome.
    García-Borreguero D; Williams AM
    Sleep Med Rev; 2010 Oct; 14(5):339-46. PubMed ID: 20219397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).
    Garcia-Borreguero D; Cano-Pumarega I; Marulanda R
    Sleep Med Rev; 2018 Oct; 41():50-60. PubMed ID: 29602660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Restless legs: recent advances in basic research and therapy].
    Sieb JP
    Med Monatsschr Pharm; 2010 Apr; 33(4):133-9. PubMed ID: 20429403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic Treatment of Restless Legs Syndrome.
    Lv Q; Wang X; Asakawa T; Wang XP
    Curr Neuropharmacol; 2021; 19(3):372-382. PubMed ID: 33380302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Treatment of Restless Legs Syndrome (RLS): An Approach to Management of Worsening Symptoms, Loss of Efficacy, and Augmentation.
    Mackie S; Winkelman JW
    CNS Drugs; 2015 May; 29(5):351-7. PubMed ID: 26045290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation in restless legs syndrome patients in Korea.
    Jeon JY; Moon HJ; Song ML; Lee HB; Cho YW
    Sleep Breath; 2015 May; 19(2):523-9. PubMed ID: 25082663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?
    Heim B; Djamshidian A; Heidbreder A; Stefani A; Zamarian L; Pertl MT; Brandauer E; Delazer M; Seppi K; Poewe W; Högl B
    Neurology; 2016 Jul; 87(1):36-40. PubMed ID: 27261093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome.
    Paulus W; Trenkwalder C
    Lancet Neurol; 2006 Oct; 5(10):878-86. PubMed ID: 16987735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
    Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
    Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation as a treatment complication of restless legs syndrome: concept and management.
    García-Borreguero D; Allen RP; Benes H; Earley C; Happe S; Högl B; Kohnen R; Paulus W; Rye D; Winkelmann J
    Mov Disord; 2007; 22 Suppl 18():S476-84. PubMed ID: 17580331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment.
    Garcia-Borreguero D; Benitez A; Kohnen R; Allen R
    Postgrad Med; 2015; 127(7):716-25. PubMed ID: 26077324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment options for restless legs syndrome.
    Wetter TC; Winkelmann J; Eisensehr I
    Expert Opin Pharmacother; 2003 Oct; 4(10):1727-38. PubMed ID: 14521483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with augmentation in patients with restless legs syndrome.
    Heim B; Ellmerer P; Stefani A; Bergmann M; Brandauer E; Seppi K; Högl B; Djamshidian A
    Eur J Neurol; 2022 Apr; 29(4):1227-1231. PubMed ID: 34923723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
    Frauscher B; Gschliesser V; Brandauer E; El-Demerdash E; Kaneider M; Rücker L; Poewe W; Högl B
    Sleep Med; 2009 Jun; 10(6):611-5. PubMed ID: 19200780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.